Costs, regulations, foreign innovation are key issues for biosimilars: US Biocom panel
This article was originally published in SRA
Executive Summary
Uncertainty abounds in regard to biosimilars – whether and how companies should enter that line of business and how large the market will be when they get there – but a select few have immersed themselves in that realm, for better or worse.
You may also be interested in...
Arena Updates Etrasimod Timelines, Introduces New Drug Candidate
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.
An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: